The Tumor Microenvironment-Dependent Transcription Factors AHR and HIF-1α Are Dispensable for Leukemogenesis in the Eµ-TCL1 Mouse Model of Chronic Lymphocytic Leukemia.

AHR HIF1α chronic lymphocytic leukemia tumor microenvironment

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
08 Sep 2021
Historique:
received: 20 08 2021
revised: 01 09 2021
accepted: 03 09 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in the elderly and is characterized by the accumulation of mature B lymphocytes in peripheral blood and primary lymphoid organs. In order to proliferate, leukemic cells are highly dependent on complex interactions with their microenvironment in proliferative niches. Not only soluble factors and BCR stimulation are important for their survival and proliferation, but also the activation of transcription factors through different signaling pathways. The aryl hydrocarbon receptor (AHR) and hypoxia-inducible factor (HIF)-1α are two transcription factors crucial for cancer development, whose activities are dependent on tumor microenvironment conditions, such as the presence of metabolites from the tryptophan pathway and hypoxia, respectively. In this study, we addressed the potential role of AHR and HIF-1α in chronic lymphocytic leukemia (CLL) development in vivo. To this end, we crossed the CLL mouse model Eµ-TCL1 with the corresponding transcription factor-conditional knock-out mice to delete one or both transcription factors in CD19+ B cells only. Despite AHR and HIF-1α being activated in CLL cells, deletion of either or both of them had no impact on CLL progression or survival in vivo, suggesting that these transcription factors are not crucial for leukemogenesis in CLL.

Identifiants

pubmed: 34572746
pii: cancers13184518
doi: 10.3390/cancers13184518
pmc: PMC8466120
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : SG
ID : 7.4502.19
Organisme : AL
ID : 7.4503.19
Organisme : IFB
ID : 7.4529.19
Organisme : GP
ID : 7.6518.20
Organisme : Fonds National de la Recherche Luxembourg to EG
ID : PRIDE15/10675146/CANBIO

Références

Front Oncol. 2017 Nov 27;7:286
pubmed: 29230384
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4
pubmed: 7539918
Haematologica. 2020 Apr;105(4):1042-1054
pubmed: 31289209
Int J Mol Sci. 2021 Jan 13;22(2):
pubmed: 33451095
Vaccines (Basel). 2020 Dec 04;8(4):
pubmed: 33291616
PLoS One. 2018 Aug 9;13(8):e0200923
pubmed: 30091999
Nat Commun. 2018 Jan 17;9(1):251
pubmed: 29343683
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
Cells. 2019 May 13;8(5):
pubmed: 31086070
Front Immunol. 2015 Mar 17;6:99
pubmed: 25852681
Haematologica. 2018 Apr;103(4):e154-e157
pubmed: 29305413
Leukemia. 2013 Jan;27(1):170-82
pubmed: 22713648
Blood Adv. 2016 Nov 22;1(1):47-61
pubmed: 29296695
Cells. 2020 Mar 20;9(3):
pubmed: 32244895
Front Immunol. 2018 Feb 13;9:286
pubmed: 29487603
Proc Natl Acad Sci U S A. 2002 May 14;99(10):6955-60
pubmed: 12011454
Cancer Cell. 2005 Jan;7(1):77-85
pubmed: 15652751
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Leuk Res. 2017 Feb;53:65-73
pubmed: 28038356
J Clin Invest. 2018 Oct 1;128(10):4682-4696
pubmed: 30198908
Cancer Cell. 2018 Mar 12;33(3):480-494.e7
pubmed: 29533786
Blood. 2018 Apr 5;131(14):1617-1621
pubmed: 29439955
Toxicol Appl Pharmacol. 2017 Feb 1;316:95-106
pubmed: 27913140
Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):363-5
pubmed: 22981691
Oncoimmunology. 2018 May 24;7(8):e1465167
pubmed: 30221064
DNA Repair (Amst). 2021 Aug 8;107:103203
pubmed: 34390915
Cell Rep. 2019 Nov 12;29(7):1878-1892.e7
pubmed: 31722204
Nat Commun. 2020 Aug 11;11(1):4011
pubmed: 32782249
Molecules. 2018 Jun 19;23(6):
pubmed: 29921764
Expert Opin Ther Targets. 2018 Nov;22(11):917-928
pubmed: 30345855
EMBO J. 2017 Jan 4;36(1):116-128
pubmed: 27875245
Mol Pharmacol. 1995 Mar;47(3):432-8
pubmed: 7700240
Exp Cell Res. 2017 Jul 15;356(2):197-203
pubmed: 28300562
Blood. 2016 Apr 21;127(16):1987-97
pubmed: 26825709
J Cancer. 2019 Jun 2;10(12):2771-2782
pubmed: 31258785
Expert Rev Hematol. 2020 Feb;13(2):109-116
pubmed: 31774349
Cold Spring Harb Perspect Med. 2021 Feb 1;11(2):
pubmed: 32229611
Cancers (Basel). 2021 Jun 09;13(12):
pubmed: 34207596
J Immunol. 2018 Jun 15;200(12):4180-4189
pubmed: 29712773
Cell. 2020 Sep 3;182(5):1252-1270.e34
pubmed: 32818467
Hematol Oncol Clin North Am. 2013 Apr;27(2):173-206
pubmed: 23561469
Semin Immunopathol. 2013 Nov;35(6):705-16
pubmed: 23942720
Cells. 2020 Apr 16;9(4):
pubmed: 32316260
Trends Pharmacol Sci. 2018 Mar;39(3):307-325
pubmed: 29254698
Oncotarget. 2017 May 30;8(22):36832-36844
pubmed: 28415662
Front Immunol. 2020 Oct 20;11:578176
pubmed: 33193376
J Exp Med. 2017 Jan;214(1):197-208
pubmed: 28011866
Blood. 2014 Jul 31;124(5):750-60
pubmed: 24850760
Am J Hematol. 2019 Nov;94(11):1266-1287
pubmed: 31364186

Auteurs

Susanne Gonder (S)

Tumor Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, L-1526 Luxembourg, Luxembourg.
Faculty of Science, Technology and Medicine, University of Luxembourg, L-4365 Esch-sur-Alzette, Luxembourg.

Anne Largeot (A)

Tumor Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, L-1526 Luxembourg, Luxembourg.

Ernesto Gargiulo (E)

Tumor Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, L-1526 Luxembourg, Luxembourg.

Sandrine Pierson (S)

Tumor Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, L-1526 Luxembourg, Luxembourg.

Iria Fernandez Botana (I)

Tumor Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, L-1526 Luxembourg, Luxembourg.
Faculty of Science, Technology and Medicine, University of Luxembourg, L-4365 Esch-sur-Alzette, Luxembourg.

Giulia Pagano (G)

Tumor Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, L-1526 Luxembourg, Luxembourg.
Faculty of Science, Technology and Medicine, University of Luxembourg, L-4365 Esch-sur-Alzette, Luxembourg.

Jerome Paggetti (J)

Tumor Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, L-1526 Luxembourg, Luxembourg.

Etienne Moussay (E)

Tumor Stroma Interactions, Department of Oncology, Luxembourg Institute of Health, L-1526 Luxembourg, Luxembourg.

Classifications MeSH